


**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 31st DECEMBER, 2014** (Rs. In Millions)

S. No.	Part - I PARTICULARS	Quarter Ended on			Nine Months Ended on		Year Ended on
		31/12/2014 Unaudited	30/09/2014 Unaudited	31/12/2013 Unaudited	31/12/2014 Unaudited	31/12/2013 Unaudited	31/03/2014 Audited
1	Net Sales/ Income from operations						
	Gross Sales	1053.18	1254.85	1304.58	3518.58	3820.33	5,195.44
	Less : Excise Duty	1.53	1.1	2.35	5.05	6.37	8.54
	(a) Net Sales	1051.65	1253.75	1302.23	3513.53	3813.96	5,186.90
	(b) Other Operating Income	3.99	5.76	10.38	16.41	23.16	73.65
	Total Income from Operation (Net)	1,055.64	1,259.51	1,312.61	3,529.94	3,837.12	5,260.55
	Expenses						
	(a) Consumption of raw materials	595.00	783.75	702.41	2008.17	2159.03	3,012.81
	(b) (Increase)/ Decrease in stock in trade	37.48	1.31	(7.53)	87.91	12.18	(23.22)
	(c) Employee benefits expense	68.05	68.99	59.95	200.46	178.78	255.65
	(d) Depreciation & amortisation expense	83.00	82.29	97.17	276.59	289.39	386.09
	(e) Other expenses	167.88	138.24	199.73	482.57	489.02	683.03
	Total expense	951.41	1,074.58	1,051.73	3,055.70	3,128.40	4,314.36
3	Profit from operations before other income , finance costs and exceptional items (1-2)	104.23	184.93	260.88	474.24	708.72	946.19
	EBIDTA (3+2(d))	187.23	267.22	358.05	750.83	998.11	1,332.28
4	Other income	1.16	1.12	0.71	3.28	2.14	4.06
5	Profit before finance costs and exceptional items (3+4)	105.39	186.05	261.59	477.52	710.86	950.25
6	Finance Costs	83.97	83.01	83.43	250.57	219.45	292.93
7	Profit after finance costs but before exceptional items (5-6)	21.42	103.04	178.16	226.95	491.41	657.32
8	Exceptional items	0.00	0.00	0.00	0.00	0	00.00
9	Profit from ordinary activities before tax (7+8)	21.42	103.04	178.16	226.95	491.41	657.32
10	Tax expense	0.00	0.00	5.88	0.00	23.00	47.82
11	Profit from ordinary activities after tax (9-10)	21.42	103.04	172.28	226.95	468.41	609.50
12	Exceptional items (net of tax expense	00.00	00.00	0.00	0.00	0.00	0.00
13	Net profit for the period (11-12)	21.42	103.04	172.28	226.95	468.41	609.50
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	4,559.73
16	E.P.S - Basic not annualised for the qtr	1.87	9.01	15.06	14.88	40.94	54.19
	- Annualised	7.49	36.02	60.23	19.84	54.58	54.19
	Part - II						
1	Public Shareholding						
	- Number of Shares	7711988	7520988	6437086	7711988	6437086	6437086
	- Percentage of Shareholding	67.40	65.73	56.26	67.40	56.26	56.26
2	Promoters and promoter group shareholding						
a)	Pledged as collateral security to bank						
	- Number of Shares	1430000	1330000	1930000	1430000	1930000	2080000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	38.34	33.92	38.56	38.34	38.56	41.56
	- Percentage of shares (as a % of the total share capital	12.50	11.62	16.87	12.50	16.87	18.18
b)	Non-Encumbered						
	- Number of Shares	2300000	2591000	3074902	2300000	3074902	2924902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	61.66	66.08	61.44	61.66	61.44	58.44
	- Percentage of shares (as a % of the total share capital	20.10	22.65	26.87	20.10	26.87	25.56

Particulars	Quarter ended 31.12.2014
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	2
Received during the quarter	NIL
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	NIL


For **VENUS REMEDIES LIMITED**

CHAIRMAN & MANAGING DIRECTOR



Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting
2. During the Quarter Venus Remedies received marketing authorization in SWITZERLAND from Swiss drug authority (SWISSMEDIC) for its generic product Meropenem.
3. Investor Complaints pending during the beginning of the quarter-two, Received during the quarter-NIL, Disposed of during the quarter-two, Remaining unresolved at the end of the quarter-NIL.
4. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

**For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED**


**(Pawan Chaudhary)
Chairman & Managing Director**

Date : 13.02.2015